Join us for the Crinetics Pharmaceuticals KOL webinar, featuring key opinion leaders Beverly MK Biller, M.D. (Massachusetts General Hospital) and Karen JP Liebert, R.N., B.S.N, (Massachusetts General Hospital), who will discuss the current landscape and unmet medical need in acromegaly, as well as the treatment burden associated with standard-of-care injectable somatostatin receptor ligands (SRLs).

In addition, the Crinetics management team will discuss its pipeline of internally-discovered oral small molecule drug candidates, with a focus on the ongoing Phase 3 PATHFNDR-1 study of paltusotine, an investigational, once-daily oral small molecule somatostatin receptor type 2 agonist. Topline data from PATHFNDR-1 are expected in the third quarter of 2023.

A live question and answer session will follow the formal presentations.